topotecan has been researched along with Diarrhea in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (38.46) | 18.2507 |
2000's | 6 (46.15) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Billups, CA; Brennan, RC; Hoehn, ME; Mao, S; Qaddoumi, I; Rodriguez-Galindo, C; Stewart, CF; Wilson, MW; Wu, J | 1 |
DeBernardo, RL; Eaton, SM; Frasure, HE; Fusco, NL; Heugel, AM; Smith, DA; von Gruenigen, VE; Waggoner, SE | 1 |
Devereux, L; Goldberg, J; Grana, G; Hageboutros, A; Khatri, J; Rodman, WD; Sbar, EI; Tritschler, L | 1 |
Goldwasser, F; Gross-Goupil, M; Hasbini, A; Lokiec, F; Lopez, G; Misset, JL; Romain, D; Tigaud, JM | 1 |
Berlin, J; Boothman, D; Forouzannia, A; Hutson, P; Mehta, M; Schiller, J; Storer, B; Wilding, G | 1 |
Holcombe, RF; Kong, KM; Wimmer, D | 1 |
Curtin, JP; Dellenbaugh, C; Hamilton, A; Hochster, H; Lee, S; Liebes, L; Mirchandani, D; Muggia, FM; Sorich, J; Yee, H | 1 |
Bonneterre, J | 1 |
Abbruzzese, JL; al-Bitar, M; Andreeff, M; Arbuck, S; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Moore, M; O'Brien, S; Pierce, S | 1 |
Broom, C; Burris, HA; Creemers, GJ; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; Verweij, J; Von Hoff, DD | 1 |
Abbruzzese, JL; Ellis, AL; Hess, KR; Loughlin, S; Madden, T; Newman, RA; Raber, MN; Sugarman, SM; Zwelling, LA | 1 |
Burris, H; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van der Burg, ME; Verweij, J; Von Hoff, DD | 1 |
Beckman, RA; Gore, M; Hearn, S; Lane, SR; Ross, G; Rustin, G; Schüller, J | 1 |
1 review(s) available for topotecan and Diarrhea
Article | Year |
---|---|
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
11 trial(s) available for topotecan and Diarrhea
Article | Year |
---|---|
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Uterine Neoplasms | 2012 |
Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 2002 |
Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Synergism; Female; Fever; Humans; Infections; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Patient Dropouts; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Diarrhea; Esophagitis; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiation-Sensitizing Agents; Thoracic Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome | 2004 |
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting | 2004 |
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liposomes; Male; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome; Vomiting | 2005 |
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Fever; Follow-Up Studies; Genes, ras; Humans; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Stomatitis; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 1997 |
Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Headache; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Skin Diseases; Thrombocytopenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome; Vomiting | 1996 |
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukopenia; Middle Aged; Neoplasms; Topotecan | 1999 |
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
Topics: Abdominal Pain; Adult; Aged; Alopecia; Antineoplastic Agents; Diarrhea; Fatigue; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Nausea; Ovarian Neoplasms; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome; Vomiting | 2001 |
1 other study(ies) available for topotecan and Diarrhea
Article | Year |
---|---|
Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Diarrhea; Disease-Free Survival; Eye Enucleation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infant; Male; Radiotherapy; Retinoblastoma; Salvage Therapy; Survival Rate; Topotecan; Vincristine; Vision Disorders; Visual Acuity | 2017 |